Activated protein C and acute kidney injury: Selective targeting of PAR-1

Akanksha Gupta, Mark D. Williams, William L. Macias, Bruce Molitoris, Brian W. Grinnell

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Protein C is a plasma serine protease that when activated plays a central role in modulating the function of the vascular endothelium and its interface with the innate immune system. Activated protein C (APC) has a dual mechanism of action via the feedback inhibition of thrombin generation, and as an agonist of protease activated receptor-1 (PAR-1). Through different cofactor interactions, this dual mechanism of antithrombotic and cytoprotective activity results in the ability of APC to modulate endothelial dysfunction by blocking cytokine signaling, functional cell adhesion expression, vascular permeability, apoptosis, and modulating leukocyte migration and adhesion. Deficiency in protein C, which occurs during systemic inflammatory activation, is highly associated with organ dysfunction. APC has shown efficacy in a number of preclinical models of thrombosis and ischemia, and the recombinant human APC drotrecogin alfa (activated), reduces mortality in patients with high-risk severe sepsis. The ability of APC to suppress pro-inflammatory pathways and enhance cellular survival suggests that APC plays a key role in the adaptive response to protect the vessel wall from insult and to enhance endothelial, cellular, and organ survival. The focus of this review will be to summarize the emerging data suggesting the potential therapeutic benefit of APC and related members of the pathway in the prevention and treatment of acute kidney injury.

Original languageEnglish
Pages (from-to)1212-1226
Number of pages15
JournalCurrent Drug Targets
Volume10
Issue number12
DOIs
StatePublished - 2009

Fingerprint

PAR-1 Receptor
Protein C
Acute Kidney Injury
Protein C Deficiency
Tissue Survival
Vascular Endothelium
Capillary Permeability
Serine Proteases
Immune system
Cell adhesion
Cell Adhesion
Thrombin
Immune System
Sepsis
Thrombosis
Leukocytes
Ischemia
Adhesion
Apoptosis
Cytokines

Keywords

  • Activated protein C
  • Acute kidney injury
  • Apoptosis
  • EPCR
  • Inflammation
  • PAR-1
  • Thrombin
  • Thrombomodulin

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Activated protein C and acute kidney injury : Selective targeting of PAR-1. / Gupta, Akanksha; Williams, Mark D.; Macias, William L.; Molitoris, Bruce; Grinnell, Brian W.

In: Current Drug Targets, Vol. 10, No. 12, 2009, p. 1212-1226.

Research output: Contribution to journalArticle

Gupta, Akanksha ; Williams, Mark D. ; Macias, William L. ; Molitoris, Bruce ; Grinnell, Brian W. / Activated protein C and acute kidney injury : Selective targeting of PAR-1. In: Current Drug Targets. 2009 ; Vol. 10, No. 12. pp. 1212-1226.
@article{9b7e5d426406450caa3191c9d20fda89,
title = "Activated protein C and acute kidney injury: Selective targeting of PAR-1",
abstract = "Protein C is a plasma serine protease that when activated plays a central role in modulating the function of the vascular endothelium and its interface with the innate immune system. Activated protein C (APC) has a dual mechanism of action via the feedback inhibition of thrombin generation, and as an agonist of protease activated receptor-1 (PAR-1). Through different cofactor interactions, this dual mechanism of antithrombotic and cytoprotective activity results in the ability of APC to modulate endothelial dysfunction by blocking cytokine signaling, functional cell adhesion expression, vascular permeability, apoptosis, and modulating leukocyte migration and adhesion. Deficiency in protein C, which occurs during systemic inflammatory activation, is highly associated with organ dysfunction. APC has shown efficacy in a number of preclinical models of thrombosis and ischemia, and the recombinant human APC drotrecogin alfa (activated), reduces mortality in patients with high-risk severe sepsis. The ability of APC to suppress pro-inflammatory pathways and enhance cellular survival suggests that APC plays a key role in the adaptive response to protect the vessel wall from insult and to enhance endothelial, cellular, and organ survival. The focus of this review will be to summarize the emerging data suggesting the potential therapeutic benefit of APC and related members of the pathway in the prevention and treatment of acute kidney injury.",
keywords = "Activated protein C, Acute kidney injury, Apoptosis, EPCR, Inflammation, PAR-1, Thrombin, Thrombomodulin",
author = "Akanksha Gupta and Williams, {Mark D.} and Macias, {William L.} and Bruce Molitoris and Grinnell, {Brian W.}",
year = "2009",
doi = "10.2174/138945009789753291",
language = "English",
volume = "10",
pages = "1212--1226",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "12",

}

TY - JOUR

T1 - Activated protein C and acute kidney injury

T2 - Selective targeting of PAR-1

AU - Gupta, Akanksha

AU - Williams, Mark D.

AU - Macias, William L.

AU - Molitoris, Bruce

AU - Grinnell, Brian W.

PY - 2009

Y1 - 2009

N2 - Protein C is a plasma serine protease that when activated plays a central role in modulating the function of the vascular endothelium and its interface with the innate immune system. Activated protein C (APC) has a dual mechanism of action via the feedback inhibition of thrombin generation, and as an agonist of protease activated receptor-1 (PAR-1). Through different cofactor interactions, this dual mechanism of antithrombotic and cytoprotective activity results in the ability of APC to modulate endothelial dysfunction by blocking cytokine signaling, functional cell adhesion expression, vascular permeability, apoptosis, and modulating leukocyte migration and adhesion. Deficiency in protein C, which occurs during systemic inflammatory activation, is highly associated with organ dysfunction. APC has shown efficacy in a number of preclinical models of thrombosis and ischemia, and the recombinant human APC drotrecogin alfa (activated), reduces mortality in patients with high-risk severe sepsis. The ability of APC to suppress pro-inflammatory pathways and enhance cellular survival suggests that APC plays a key role in the adaptive response to protect the vessel wall from insult and to enhance endothelial, cellular, and organ survival. The focus of this review will be to summarize the emerging data suggesting the potential therapeutic benefit of APC and related members of the pathway in the prevention and treatment of acute kidney injury.

AB - Protein C is a plasma serine protease that when activated plays a central role in modulating the function of the vascular endothelium and its interface with the innate immune system. Activated protein C (APC) has a dual mechanism of action via the feedback inhibition of thrombin generation, and as an agonist of protease activated receptor-1 (PAR-1). Through different cofactor interactions, this dual mechanism of antithrombotic and cytoprotective activity results in the ability of APC to modulate endothelial dysfunction by blocking cytokine signaling, functional cell adhesion expression, vascular permeability, apoptosis, and modulating leukocyte migration and adhesion. Deficiency in protein C, which occurs during systemic inflammatory activation, is highly associated with organ dysfunction. APC has shown efficacy in a number of preclinical models of thrombosis and ischemia, and the recombinant human APC drotrecogin alfa (activated), reduces mortality in patients with high-risk severe sepsis. The ability of APC to suppress pro-inflammatory pathways and enhance cellular survival suggests that APC plays a key role in the adaptive response to protect the vessel wall from insult and to enhance endothelial, cellular, and organ survival. The focus of this review will be to summarize the emerging data suggesting the potential therapeutic benefit of APC and related members of the pathway in the prevention and treatment of acute kidney injury.

KW - Activated protein C

KW - Acute kidney injury

KW - Apoptosis

KW - EPCR

KW - Inflammation

KW - PAR-1

KW - Thrombin

KW - Thrombomodulin

UR - http://www.scopus.com/inward/record.url?scp=72849119793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72849119793&partnerID=8YFLogxK

U2 - 10.2174/138945009789753291

DO - 10.2174/138945009789753291

M3 - Article

C2 - 19715537

AN - SCOPUS:72849119793

VL - 10

SP - 1212

EP - 1226

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 12

ER -